Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma
Purpose Studies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse. Methods This retrospective cohort study inves...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2022-05, Vol.148 (5), p.1211-1222 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1222 |
|---|---|
| container_issue | 5 |
| container_start_page | 1211 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 148 |
| creator | Cheng, Chieh-Lung Fang, Wei-Quan Lin, Yu-Jen Yuan, Chang-Tsu Ko, Bor-Sheng Tang, Jih-Luh Tien, Hwei-Fang |
| description | Purpose
Studies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse.
Methods
This retrospective cohort study investigated the prognostic impact of HBsAg in immunocompetent patients with FL treated with frontline rituximab-containing chemoimmunotherapy in an HBV-endemic area between 2006 and 2016.
Results
Among the 149 analyzed patients, 32 (21.5%) were HBsAg-positive. HBsAg positivity was positively associated with symptomatic splenomegaly, significant serous effusions, and peritreatment hepatic dysfunction. HBsAg-positive patients had a trend of lower complete remission rate (59.4% vs. 76.9%,
P
= 0.07), significantly poorer overall survival (hazard ratio for death, 2.68; 95% confidence interval, 1.21–5.92), and shorter progression-free survival than had HBsAg-negative patients. Multivariate analysis revealed that HBsAg is an independent adverse prognostic factor for overall survival. Intriguingly, HBsAg-positive patients had a higher incidence of progression of disease within 24 months (POD24) than had HBsAg-negative patients (cumulative incidence rate, 25.8% vs. 12.4%,
P
= 0.045).
Conclusion
This study revealed that patients with FL and chronic HBV infection represent a distinct subgroup with a markedly poor prognosis. HBsAg was positively associated with POD24 and might serve as a new prognostic predictor of the survival of FL patients in endemic regions for HBV infection. |
| doi_str_mv | 10.1007/s00432-021-03719-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2548907441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548907441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-ef807244a8838e5da9da4dbb0bb95abddbe3b11835a7d034a7e67568213759fd3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS1ERS-FF2CBLLFhE-rfOFlCBRSpUjdlbTnx5F5XSRw8DlXehmfhyXB7C0gsWFnj850zIx1CXnH2jjNmzpExJUXFBK-YNLyttidkx--_uJT6KdkxbnilBa9PyXPEW1ZmbcQzciqVEI0Qake2S1hcDjkg_UBxTYPrgbo5hz3MdIlYlO8hb7ToDjH2wWXw9C7kA11S3CdADHGmcaA-IDiEBy3MVKifP6Y45wPSMg1xHEO_ji7RcZuWQ5zcC3IyuBHh5eN7Rr5--nhzcVldXX_-cvH-quql0bmCoWFGKOWaRjagvWu9U77rWNe12nXedyA7zhupnfFMKmegNrpuBC_2dvDyjLw95pZ7v62A2U4BexhHN0Nc0QqtmpYZpXhB3_yD3sY1zeU6K2rNW1bXui6UOFJ9iogJBrukMLm0Wc7sfTH2WIwtxdiHYuxWTK8fo9duAv_H8ruJAsgjgEWa95D-7v5P7C-WuZvh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2651906656</pqid></control><display><type>article</type><title>Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Cheng, Chieh-Lung ; Fang, Wei-Quan ; Lin, Yu-Jen ; Yuan, Chang-Tsu ; Ko, Bor-Sheng ; Tang, Jih-Luh ; Tien, Hwei-Fang</creator><creatorcontrib>Cheng, Chieh-Lung ; Fang, Wei-Quan ; Lin, Yu-Jen ; Yuan, Chang-Tsu ; Ko, Bor-Sheng ; Tang, Jih-Luh ; Tien, Hwei-Fang</creatorcontrib><description>Purpose
Studies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse.
Methods
This retrospective cohort study investigated the prognostic impact of HBsAg in immunocompetent patients with FL treated with frontline rituximab-containing chemoimmunotherapy in an HBV-endemic area between 2006 and 2016.
Results
Among the 149 analyzed patients, 32 (21.5%) were HBsAg-positive. HBsAg positivity was positively associated with symptomatic splenomegaly, significant serous effusions, and peritreatment hepatic dysfunction. HBsAg-positive patients had a trend of lower complete remission rate (59.4% vs. 76.9%,
P
= 0.07), significantly poorer overall survival (hazard ratio for death, 2.68; 95% confidence interval, 1.21–5.92), and shorter progression-free survival than had HBsAg-negative patients. Multivariate analysis revealed that HBsAg is an independent adverse prognostic factor for overall survival. Intriguingly, HBsAg-positive patients had a higher incidence of progression of disease within 24 months (POD24) than had HBsAg-negative patients (cumulative incidence rate, 25.8% vs. 12.4%,
P
= 0.045).
Conclusion
This study revealed that patients with FL and chronic HBV infection represent a distinct subgroup with a markedly poor prognosis. HBsAg was positively associated with POD24 and might serve as a new prognostic predictor of the survival of FL patients in endemic regions for HBV infection.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-021-03719-y</identifier><identifier>PMID: 34228224</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antigens ; Cancer Research ; Chronic infection ; Hematology ; Hepatitis B ; Hepatitis B - complications ; Hepatitis B - drug therapy ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Humans ; Infections ; Internal Medicine ; Lymphoma ; Lymphoma, Follicular - drug therapy ; Medical prognosis ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Oncology ; Original Article – Clinical Oncology ; Patients ; Prognosis ; Remission ; Retrospective Studies ; Rituximab ; Rituximab - therapeutic use ; Splenomegaly ; Survival</subject><ispartof>Journal of cancer research and clinical oncology, 2022-05, Vol.148 (5), p.1211-1222</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-ef807244a8838e5da9da4dbb0bb95abddbe3b11835a7d034a7e67568213759fd3</citedby><cites>FETCH-LOGICAL-c375t-ef807244a8838e5da9da4dbb0bb95abddbe3b11835a7d034a7e67568213759fd3</cites><orcidid>0000-0001-5442-1079</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-021-03719-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-021-03719-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34228224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Chieh-Lung</creatorcontrib><creatorcontrib>Fang, Wei-Quan</creatorcontrib><creatorcontrib>Lin, Yu-Jen</creatorcontrib><creatorcontrib>Yuan, Chang-Tsu</creatorcontrib><creatorcontrib>Ko, Bor-Sheng</creatorcontrib><creatorcontrib>Tang, Jih-Luh</creatorcontrib><creatorcontrib>Tien, Hwei-Fang</creatorcontrib><title>Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
Studies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse.
Methods
This retrospective cohort study investigated the prognostic impact of HBsAg in immunocompetent patients with FL treated with frontline rituximab-containing chemoimmunotherapy in an HBV-endemic area between 2006 and 2016.
Results
Among the 149 analyzed patients, 32 (21.5%) were HBsAg-positive. HBsAg positivity was positively associated with symptomatic splenomegaly, significant serous effusions, and peritreatment hepatic dysfunction. HBsAg-positive patients had a trend of lower complete remission rate (59.4% vs. 76.9%,
P
= 0.07), significantly poorer overall survival (hazard ratio for death, 2.68; 95% confidence interval, 1.21–5.92), and shorter progression-free survival than had HBsAg-negative patients. Multivariate analysis revealed that HBsAg is an independent adverse prognostic factor for overall survival. Intriguingly, HBsAg-positive patients had a higher incidence of progression of disease within 24 months (POD24) than had HBsAg-negative patients (cumulative incidence rate, 25.8% vs. 12.4%,
P
= 0.045).
Conclusion
This study revealed that patients with FL and chronic HBV infection represent a distinct subgroup with a markedly poor prognosis. HBsAg was positively associated with POD24 and might serve as a new prognostic predictor of the survival of FL patients in endemic regions for HBV infection.</description><subject>Antigens</subject><subject>Cancer Research</subject><subject>Chronic infection</subject><subject>Hematology</subject><subject>Hepatitis B</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens</subject><subject>Hepatitis B virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Internal Medicine</subject><subject>Lymphoma</subject><subject>Lymphoma, Follicular - drug therapy</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Remission</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>Splenomegaly</subject><subject>Survival</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc1u1TAQhS1ERS-FF2CBLLFhE-rfOFlCBRSpUjdlbTnx5F5XSRw8DlXehmfhyXB7C0gsWFnj850zIx1CXnH2jjNmzpExJUXFBK-YNLyttidkx--_uJT6KdkxbnilBa9PyXPEW1ZmbcQzciqVEI0Qake2S1hcDjkg_UBxTYPrgbo5hz3MdIlYlO8hb7ToDjH2wWXw9C7kA11S3CdADHGmcaA-IDiEBy3MVKifP6Y45wPSMg1xHEO_ji7RcZuWQ5zcC3IyuBHh5eN7Rr5--nhzcVldXX_-cvH-quql0bmCoWFGKOWaRjagvWu9U77rWNe12nXedyA7zhupnfFMKmegNrpuBC_2dvDyjLw95pZ7v62A2U4BexhHN0Nc0QqtmpYZpXhB3_yD3sY1zeU6K2rNW1bXui6UOFJ9iogJBrukMLm0Wc7sfTH2WIwtxdiHYuxWTK8fo9duAv_H8ruJAsgjgEWa95D-7v5P7C-WuZvh</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Cheng, Chieh-Lung</creator><creator>Fang, Wei-Quan</creator><creator>Lin, Yu-Jen</creator><creator>Yuan, Chang-Tsu</creator><creator>Ko, Bor-Sheng</creator><creator>Tang, Jih-Luh</creator><creator>Tien, Hwei-Fang</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5442-1079</orcidid></search><sort><creationdate>20220501</creationdate><title>Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma</title><author>Cheng, Chieh-Lung ; Fang, Wei-Quan ; Lin, Yu-Jen ; Yuan, Chang-Tsu ; Ko, Bor-Sheng ; Tang, Jih-Luh ; Tien, Hwei-Fang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-ef807244a8838e5da9da4dbb0bb95abddbe3b11835a7d034a7e67568213759fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Cancer Research</topic><topic>Chronic infection</topic><topic>Hematology</topic><topic>Hepatitis B</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens</topic><topic>Hepatitis B virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Internal Medicine</topic><topic>Lymphoma</topic><topic>Lymphoma, Follicular - drug therapy</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Remission</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>Splenomegaly</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Chieh-Lung</creatorcontrib><creatorcontrib>Fang, Wei-Quan</creatorcontrib><creatorcontrib>Lin, Yu-Jen</creatorcontrib><creatorcontrib>Yuan, Chang-Tsu</creatorcontrib><creatorcontrib>Ko, Bor-Sheng</creatorcontrib><creatorcontrib>Tang, Jih-Luh</creatorcontrib><creatorcontrib>Tien, Hwei-Fang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Chieh-Lung</au><au>Fang, Wei-Quan</au><au>Lin, Yu-Jen</au><au>Yuan, Chang-Tsu</au><au>Ko, Bor-Sheng</au><au>Tang, Jih-Luh</au><au>Tien, Hwei-Fang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>148</volume><issue>5</issue><spage>1211</spage><epage>1222</epage><pages>1211-1222</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
Studies have reported a positive association between hepatitis B surface antigen (HBsAg)-positive hepatitis B virus (HBV) infection and follicular lymphoma (FL). Nevertheless, clinical information concerning chronic HBV infection in FL is sparse.
Methods
This retrospective cohort study investigated the prognostic impact of HBsAg in immunocompetent patients with FL treated with frontline rituximab-containing chemoimmunotherapy in an HBV-endemic area between 2006 and 2016.
Results
Among the 149 analyzed patients, 32 (21.5%) were HBsAg-positive. HBsAg positivity was positively associated with symptomatic splenomegaly, significant serous effusions, and peritreatment hepatic dysfunction. HBsAg-positive patients had a trend of lower complete remission rate (59.4% vs. 76.9%,
P
= 0.07), significantly poorer overall survival (hazard ratio for death, 2.68; 95% confidence interval, 1.21–5.92), and shorter progression-free survival than had HBsAg-negative patients. Multivariate analysis revealed that HBsAg is an independent adverse prognostic factor for overall survival. Intriguingly, HBsAg-positive patients had a higher incidence of progression of disease within 24 months (POD24) than had HBsAg-negative patients (cumulative incidence rate, 25.8% vs. 12.4%,
P
= 0.045).
Conclusion
This study revealed that patients with FL and chronic HBV infection represent a distinct subgroup with a markedly poor prognosis. HBsAg was positively associated with POD24 and might serve as a new prognostic predictor of the survival of FL patients in endemic regions for HBV infection.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34228224</pmid><doi>10.1007/s00432-021-03719-y</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-5442-1079</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2022-05, Vol.148 (5), p.1211-1222 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2548907441 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Antigens Cancer Research Chronic infection Hematology Hepatitis B Hepatitis B - complications Hepatitis B - drug therapy Hepatitis B surface antigen Hepatitis B Surface Antigens Hepatitis B virus Humans Infections Internal Medicine Lymphoma Lymphoma, Follicular - drug therapy Medical prognosis Medicine Medicine & Public Health Multivariate analysis Oncology Original Article – Clinical Oncology Patients Prognosis Remission Retrospective Studies Rituximab Rituximab - therapeutic use Splenomegaly Survival |
| title | Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A06%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20surface%20antigen%20positivity%20is%20associated%20with%20progression%20of%20disease%20within%2024%C2%A0months%20in%20follicular%20lymphoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Cheng,%20Chieh-Lung&rft.date=2022-05-01&rft.volume=148&rft.issue=5&rft.spage=1211&rft.epage=1222&rft.pages=1211-1222&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-021-03719-y&rft_dat=%3Cproquest_cross%3E2548907441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2651906656&rft_id=info:pmid/34228224&rfr_iscdi=true |